Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|November 12, 2019
Trends and Insights for Your Oncology Trial: Considerations for biotech companies embarking on oncology clinical trials
Author(s)IQVIA Biotech
This complimentary webinar explores top trends influencing oncology clinical development. We will share insights and best practices to help ensure your future oncology trials are designed to be quick and efficient and yield high quality data for the best chance for success. Live: Tuesday, November 12, 2019 at 10am EST On demand available after airing until Nov. 12, 2020. Register free
Register free:
Event Overview:
A record number of new oncology drugs have been approved in recent years, bringing new treatment options to patients. However, despite robust levels of pipeline activity, oncology trials are complex and remain a challenging area for research and development.
Join this webinar to learn about trends shaping the development and delivery of cancer treatment worldwide. We will share insights and best practices to help ensure your future oncology trials are designed to be quick and efficient and yield high-quality data for the best chance of success. Our experts will address specific considerations for biotech companies embarking on oncology trials.
Key Learning Objectives:
Understand top trends driving change in oncology clinical development today and through 2023.
Recognize the impact of new therapies and care standards on trial planning and design.
Learn how to apply real world evidence to trial design, trial start-up, and trial conduct for more efficient and effective trials.
Speakers: Murray Aitken, Executive Director, IQVIA Institute for Human Data Science
Andrew Zupnick, Ph.D., Vice President, Oncology Strategy, IQVIA Biotech
Time and date: Tuesday, November 12, 2019 at 10am EST
On demand available after airing until Nov. 12, 2020.
Sponsor: IQVIA
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5